APAC Liquid Biopsy Market Industry Trends and Forecast to 2034: Segmented by (Biomarker, Application, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Overview
Market Dashboard
APAC · 2024–2034 · placeholder estimates
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the
full report.
Estimate 2024$1.69 BnPlaceholder estimate
Estimate 2025$2.00 Bn22.4% of the global market
Projected 2034$8.86 Bn 343.5%Adds $6.86 Bn over 9 forecast years
CAGR 2025–203418.0%Faster than 90% of 173 Medical Devices markets here
Guardant Health, Inc., Roche, GRAIL, Natera, Exact Sciences Corporation and 1 more (see all)
Active clinical trials
54 in Asia PacificSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Asia Pacific. Retrieved 12 Nov 2026.
Formats
PDF, PPTX, XLSX
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
The APAC Liquid Biopsy Market Analysis Executive Summary
Liquid biopsy finds cancer signals such as tumour DNA in a blood sample, to detect cancer, guide treatment and check for relapse.
Key segments of the liquid Biopsy market include biomarker (Circulating Tumor DNA, Circulating Tumor Cells and Exosomes) and application (Treatment Selection, Recurrence Monitoring and Early Detection).
Asia Pacific Liquid Biopsy market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.
APAC Liquid Biopsy Market Dynamics
Market Growth Drivers
Rising cancer cases, earlier detection, precision medicine and a strong pipeline of targeted and immune therapies are driving the liquid Biopsy market. Faster approvals and new combinations are improving survival.
Opportunity
Biomarker-led treatment, earlier lines of therapy and expansion into emerging markets offer strong growth for the liquid Biopsy market.
Market Restraints
High treatment costs, drug resistance, side effects and unequal access to cancer centres hold back the liquid Biopsy market, especially in low- and middle-income countries.
Competitive Landscape for Liquid Biopsy Market in APAC
The liquid Biopsy market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
Healthcare Policies and Regulatory Landscape for Liquid Biopsy Market in APAC
Liquid Biopsy in APAC: rules, payment and research
In some of the countries we cover here, medical devices are regulated by TGA (Australia)[1], NMPA (China)[2], MDACS (Hong Kong)[3], CDSCO (India)[4], PMDA (Japan)[5], MDA (Malaysia)[6], Medsafe (WAND) (New Zealand)[7], FDA Philippines (Philippines)[8], HSA (Singapore)[9] and Thai FDA (Thailand)[10]. How care is paid for in some of these countries: Medicare and the PBS (Australia)[11], basic medical insurance (China)[12], the Hospital Authority (Hong Kong)[13], Ayushman Bharat PM-JAY (India)[14], public health insurance (Japan)[15], subsidised public care (Malaysia)[16], Pharmac (New Zealand)[17], PhilHealth (Philippines)[18], MediShield Life (Singapore)[19] and the Universal Coverage Scheme (Thailand)[20]. ClinicalTrials.gov lists 54 studies on Liquid Biopsy that are recruiting, active or about to start in APAC.[21]
[21]ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in APAC. Retrieved 12 Nov 2026.
Policy changes and Reimbursement scenario
Medical device rules, such as the US FDA 510(k) and PMA pathways and the EU Medical Device Regulation, govern how liquid Biopsy products are approved and monitored. Reimbursement codes and hospital purchasing policies decide how widely they are used in APAC.
2.2 Market Size, Growth Prospects and Key findings
3 Market Dynamics
3.1 Market Growth Drivers Analysis
3.2 Market Restraints Analysis
4 Market Segmentation
4.1 By Biomarker
4.2 By Application
4.3 By End User
5 By Market Share
5.1 Market Analysis, Insights and Forecast – By Revenue
6 Competitive Landscape
6.1 Major Top Market Players Products in Pipeline
6.2 R&D Initiatives
6.3 Notable recent Deals
6.3.1 Strategic Divestments
6.3.2 Mergers & Acquisitions
6.3.3 Partnerships
6.3.4 Joint Ventures
7 Key Company Profiles
7.1 Guardant Health
7.2 Roche (Foundation Medicine)
7.3 GRAIL
7.4 Natera
7.5 Exact Sciences
7.6 Illumina
8 Healthcare Policies and Regulatory Landscape
8.1 Policy changes and Reimbursement scenario
8.2 Government Initiatives / Intervention programs
The liquid Biopsy market can be segmented based on various criteria, including biomarker, application and end user. Here's a breakdown of the market segmentation
Other companies that free public records show in this market: trials they lead, US approvals and WHO prequalification. They are not part of our key players research. Each count opens its source.
Also active in this area, from free public records
Source: ClinicalTrials.gov, Active studies (recruiting, about to start or running) each company leads, found with this market's trial search, worldwide. Retrieved 13 Nov 2026.
Beyond the market numbers
Research, trials and patients
What doctors and scientists are doing in Liquid Biopsy right now, from free public sources.
Clinical trials
54 active trials in China, India, Japan, Australia, Hong Kong, Philippines, Singapore, Thailand, Malaysia, New Zealand, Bangladesh, Afghanistan, Indonesia, Myanmar, Nepal and Pakistan
Recruiting, about to start, or running now. Counted across the 16 countries we report on in APAC.
Sources:PubMed (US National Library of Medicine),
ClinicalTrials.gov.
Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
How big is the Liquid Biopsy market in Asia Pacific?
Placeholder estimate: about $2.00 Bn in 2025, rising to about $8.86 Bn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Liquid Biopsy market in Asia Pacific growing?
Placeholder estimate: about 18.0% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Liquid Biopsy market report cover?
The report splits the market by biomarker (Circulating Tumor DNA, Circulating Tumor Cells, Exosomes), application (Treatment Selection, Recurrence Monitoring, Early Detection) and end user (Hospitals, Ambulatory Surgical Centers, Diagnostic Centers, Home Care Settings).
Who are the key players in the Liquid Biopsy market?
Key players include Guardant Health, Inc., Roche, GRAIL, Natera, Exact Sciences Corporation and Illumina, Inc..
What is driving the Liquid Biopsy market?
Rising cancer cases, earlier detection, precision medicine and a strong pipeline of targeted and immune therapies are driving the liquid Biopsy market. Faster approvals and new combinations are improving survival.
How many clinical trials on Liquid Biopsy are running in Asia Pacific?
54 studies are recruiting, active or about to start in Asia Pacific, counted across the 16 countries we report on there, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Asia Pacific. Retrieved 12 Nov 2026.
How much research is published on Liquid Biopsy?
PubMed lists 10,752 papers on Liquid Biopsy added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
US
China
Canada
Japan
Germany
UK
France
Brazil
Spain
Ecuador
Italy
Saudi Arabia
India
Mexico
Russia
Australia
New Zealand
South Africa
UAE
Egypt
Philippines
Hong Kong
Malaysia
Singapore
Thailand
Kenya